Brexanolone Injection (Zulresso)

Brexanolone (Zulresso) is covered only as a one‑time 60‑hour IV infusion (up to 90 mcg/kg/hr) per postpartum period for adults (≥18) with FDA‑approved moderate‑to‑severe postpartum depression whose symptoms began in the third trimester or within 4 weeks after delivery, and is excluded for pregnant individuals, mild PPD, symptom onset outside that window, beyond 6 months postpartum, or repeat dosing. Approval requires documentation of diagnosis and symptom onset timing, patient age, ≤6 months postpartum and not pregnant, prescribing or consultation by a psychiatrist or OB‑GYN, a planned dosing/administration plan, and compliance with applicable safety/REMS requirements.

"Treatment of postpartum depression (PPD) in adults."

Sign up to see full coverage criteria, indications, and limitations.